42 completed. 42 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 42 | Completed 42 |
Follow Healthy Volunteer Study: new trials by email Literature Review of Healthy Volunteer Study trials Research Report on Healthy Volunteer Study
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR), Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 24 | 2025-12-04 | 2026-04-13 |
| Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 20 | 2025-05-09 | 2025-08-29 |
| Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination - Healthy Volunteer Study, Hepatic Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 28 | 2025-04-09 | 2026-07-31 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 38 | 2025-04-08 | 2025-08-29 |
| A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations ALG-055009 - Healthy Volunteer Study | Phase 1 | Completed | Aligos Therapeutics | 8 | 2025-03-25 | 2025-07-09 |
| A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects CG001419, Placebo - Healthy Volunteer Study, Pain Management | Phase 1 | Completed | Cullgen Australia Pty Ltd | 72 | 2025-01-22 | 2026-02-20 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 30 | 2025-01-07 | 2026-10-28 |
| Phase 1 BIO 300 Oral Suspension BIO 300 Oral Suspension - Healthy Volunteer Study | Phase 1 | Completed | Humanetics Corporation | 56 | 2024-12-23 | 2025-10-30 |
| A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers TRX-100, Placebo - Healthy Volunteer Study | Phase 1 | Completed | Traws Pharma, Inc. | 66 | 2024-08-13 | 2026-01-21 |
| Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK, Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 28 | 2024-04-15 | 2024-07-31 |
| A Clinical Study of AK0610 AK0610 Injection solution, Placebo - Healthy Volunteer Study | Phase 1 | Completed | Shanghai Ark Biopharmaceutical Co., Ltd. | 147 | 2024-02-29 | 2026-10-28 |
| Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe Fixed-Dose Combination (FDC) Tablet - Healthy Volunteer Study | Phase 1 | Completed | NewAmsterdam Pharma | 28 | 2024-01-20 | 2024-06-05 |
| Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 42 | 2023-12-14 | 2024-09-19 |
| Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers Azelaprag - Healthy Volunteer Study | Phase 1 | Completed | BioAge Labs, Inc. | 16 | 2023-11-17 | 2024-02-23 |
| Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744. BEN8744, Matching Placebo - Healthy Volunteer Study | Phase 1 | Completed | BenevolentAI Bio | 76 | 2023-08-30 | 2025-05-07 |
| The Study of Bemnifosbuvir in Healthy Japanese Subjects Bemnifosbuvir (BEM) - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 14 | 2023-04-26 | 2023-06-15 |
| Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects Bemnifosbuvir (BEM), Placebo, Moxifloxacin - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 35 | 2023-04-25 | 2023-06-15 |
| A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects intravenous oxytocin, intranasal oxytocin - Healthy Volunteer Study | Phase 1 | Completed | Wake Forest University Health Sciences | 25 | 2023-02-27 | 2025-02-17 |
| Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 32 | 2023-01-30 | 2023-06-01 |
| A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers KNX100 - Healthy Volunteer Study, Opioid-use Disorder | Phase 1 | Completed | Kinoxis Therapeutics Pty Ltd | 57 | 2022-04-07 | 2025-01-06 |
Showing 20 of 42. Sign in to see all of them.
Acute Pain (1) · Acute Radiation Syndrome (1) · Agnosia (1) · Chronic Pain (1) · Opioid-Related Disorders (1) · Renal Insufficiency (1)
Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Chemically-Induced Disorders (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Mental Disorders (1) · Narcotic-Related Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Pain (1) · Perceptual Disorders (1) · Radiation Injuries (1)
AT-511 (12) · ruzasvir (3) · Ibuprofen (2) · Tablets (2) · Acetaminophen (1) · Buprenorphine (1) · Carbamazepine (1) · Cyclosporine (1) · Fluticasone-Salmeterol Drug Combination (1) · LY 2140023 (1) · Lead (1) · Levonorgestrel (1) · Midazolam (1) · Moxifloxacin (1) · Naloxone (1)
Atea Pharmaceuticals, Inc. (18) · Orion Corporation, Orion Pharma (3) · Reckitt Benckiser Healthcare (UK) Limited (2) · Aligos Therapeutics (1) · AstraZeneca (1) · BenevolentAI Bio (1) · BioAge Labs, Inc. (1) · Cullgen Australia Pty Ltd (1) · Dauntless Pharmaceuticals (1) · Denovo Biopharma LLC (1) · Exicure, Inc. (1) · Humanetics Corporation (1) · Kinoxis Therapeutics Pty Ltd (1) · London School of Hygiene and Tropical Medicine (1) · NewAmsterdam Pharma (1)
United States (13) · Canada (12) · United Kingdom (8) · Australia (3) · Finland (2) · China (1) · France (1) · Germany (1) · New Zealand (1)
Denisa Wilkes (1) · Girish Sharma, MBBS (1) · Haleema Shakur-Still (1) · Ian Roberts (1) · James C Eisenach, MD (1) · Jeffrey Zacher, MD (1) · Jo Collier, Dr,MB, ChB (1) · John Whiteside (1) · Maria Annunen, MSc (1) · Mika Scheinin, MD, PhD (1) · Patrick Martin, MD (1) · Rainard Fuhr, MD (1) · Tina Soulis, PhD (1)
PMID 29667449, PMID 30977980, PMID 34998508, PMID 36582243, PMID 40121179
1UG3DA048743-01 (1), 2014 (1), P01NS119159 (1)